Further, it is also an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

The single-dose vial presentation has marketing authorization from the national drugs regulator—Central Drugs Standard ...

The much-awaited launch of Mounjaro, an injectable drug used to treat obesity, overweight, and type 2 diabetes, has been ...

Mounjaro is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management ...

US pharma giant Eli Lilly's Mounjaro can prove crucial in treatment of obesity & type 2 diabetes. Launched in the US in 2022, ...

Global pharmaceutical company Eli Lilly and Company (India) has introduced Mounjaro (tirzepatide) in India, a breakthrough drug for the treatment of Type 2 diabetes and obesity. Approved by the ...

Once-a-weekly, prescription-based medicine, Mounjaro is a single molecule that selectively binds to and activates both GIP ...

Eli Lilly and Company (India) on Thursday said it has launched a first-of-its-kind medication for obesity and type 2 diabetes ...

The company said it has introduced Mounjaro in a single-dose vial presentation following the marketing authorisation from the ...

Brentwood, Tennessee Saturday, March 22, 2025, 13:00 Hrs [IST] ...

Lilly launches Mounjaro in India, offering new option to treat obesity and type 2 diabetes: Our Bureau, Bengaluru Thursday, ...

The Indian subsidiary of US pharma major Eli Lilly (NYSE: LLY) has announced the launch of Mounjaro (tirzepatide) in ...